Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for FMC7 returned no results
Showing 451 to 476 of 476 results for face

  1. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (TA195)

    Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), rituximab (MabThera) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried other disease-modifying antirheumatic drugs (DMARDs) but cannot tolerate them or they have not worked well enough.

  2. Donor milk banks: service operation (CG93)

    This guideline covers how donor milk banks should recruit, screen and support women who donate breast milk. It also covers how milk banks should handle and process the breast milk they receive from donors. It aims to improve the safety of donor milk and operation of donor milk services.

  3. Depression in adults with a chronic physical health problem: recognition and management (CG91)

    This guideline covers identifying, treating and managing depression in people aged 18 and over who also have a chronic physical health problem such as cancer, heart disease or diabetes. It aims to improve the care of people with a long-term physical health problem, which can cause or exacerbate depression. This has the potential to increase their quality of life and life expectancy.

  4. Pemetrexed for the first-line treatment of non-small-cell lung cancer (TA181)

    Evidence-based recommendations on pemetrexed for untreated non-small-cell lung cancer in adults.

  5. Placement of pectus bar for pectus excavatum (also known as MIRPE or the Nuss procedure) (HTG199)

    Evidence-based recommendations on placement of pectus bar for pectus excavatum (Nuss procedure). This involves placing one or two steel (pectus) bars under the breastbone with the aim of raising it and correcting the abnormal shape.

  6. Diarrhoea and vomiting caused by gastroenteritis in under 5s: diagnosis and management (CG84)

    This guideline covers diagnosing, managing and referring infants and young children younger than 5 years who present with acute diarrhoea (lasting up to 14 days) with or without vomiting. It aims to improve the diagnosis and management of infective gastroenteritis and appropriate escalation of care.

  7. Rehabilitation after critical illness in adults (CG83)

    This guideline covers rehabilitation strategies for adults who have experienced a critical illness and stayed in critical care. It aims to improve physical, psychological and cognitive outcomes in people who have been discharged from critical care.

  8. Balloon catheter dilation of paranasal sinus ostia for chronic sinusitis (HTG174)

    Evidence-based recommendations on balloon catheter dilation of paranasal sinus ostia for chronic sinusitis. This involves gently inflating a small balloon, which is introduced through the nose via a flexible tube, to help keep the sinus passages open and unobstructed.

  9. Lumbar infusion test for the investigation of normal pressure hydrocephalus (HTG169)

    Evidence-based recommendations on the lumbar infusion test for the investigation of normal pressure hydrocephalus. This involves inserting a lumbar needle into the spinal sac, recording the pressure of the CSF as fluid is infused into the sac.

  10. Interstitial photodynamic therapy for malignant parotid tumours (HTG166)

    Evidence-based recommendations on interstitial photodynamic therapy for malignant parotid tumours. This involves injecting a photosensitising agent into a vein and using a special light to activate it and destroy the tumour cells.

  11. Drug misuse in over 16s: opioid detoxification (CG52)

    This guideline covers helping adults and young people over 16 who are dependent on opioids to stop using drugs. It aims to reduce illicit drug use and improve people’s physical and mental health, relationships and employment.

  12. Therapeutic sialendoscopy (HTG140)

    Evidence-based recommendations on therapeutic sialendoscopy. This involves using a flexible tube to enter the salivary gland, and visualise and remove the stone.

  13. Tonsillectomy using laser (HTG120)

    Evidence-based recommendations on tonsillectomy using laser. This involves using a laser to cut and remove tonsils and seal the blood vessels.

  14. Improving outcomes for people with brain and other central nervous system tumours (CSG10)

    This guideline covers how healthcare services for people with brain tumours and other central nervous system tumours should be organised. It aims to improve care by recommending which healthcare professionals should be involved and the types of hospital or cancer centre best suited to provide the care.

  15. Frequency of application of topical corticosteroids for atopic eczema (TA81)

    Evidence-based recommendations on using topical corticosteroids for people with atopic eczema.

  16. Tacrolimus and pimecrolimus for atopic eczema (TA82)

    Evidence-based recommendations on tacrolimus (Protopic) and pimecrolimus (Elidel) for people with atopic eczema.

  17. Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]

    Discontinued Reference number: GID-TA10764

  18. Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959]

    In development Reference number: GID-TA10868 Expected publication date:  15 July 2026

  19. Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]

    Discontinued Reference number: GID-TA10596

  20. Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]

    Discontinued Reference number: GID-TA10597

  21. Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6440]

    In development Reference number: GID-TA11554 Expected publication date: TBC

  22. Digital technologies delivering CBT for insomnia in adults

    In development Reference number: GID-HTE10068 Expected publication date:  06 January 2027

  23. Digital platforms to support rehabilitation before and after primary elective hip or knee replacement surgery

    In development Reference number: GID-HTE10069 Expected publication date:  11 August 2026

  24. Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer ID6406

    In development Reference number: GID-TA11341 Expected publication date:  02 December 2026

  25. Ex-situ machine perfusion devices for extracorporeal preservation of lungs for transplant

    In development Reference number: GID-HTE10084 Expected publication date: TBC

  26. Nemolizumab for treating prurigo nodularis [ID6451]

    In development Reference number: GID-TA11566 Expected publication date: TBC